The People over 65 years old They are no longer human high risk for hospital admission due to Covid-19 People at medium risk. This has been noted by the World Health Organization (WHO), which has updated its guidelines on the treatment of patients with this disease. Adaptation to the current lower risk of serious illness.
This is because the update includes new risk assessments Reference for hospitalization in patients with non-severe Covid-19. “The new intermediate-risk category now includes people previously considered high-risk, including older people and/or people with chronic diseases, disabilities and comorbidities of chronic diseases,” summarizes the WHO.
Therefore, immunosuppressed people continue to be at higher risk (high risk) if they contract Covid-19, with an estimated hospitalization rate of 6 percent. He moderate risk Now includes people over 65 years of age, people with medical conditions such as obesity, diabetes and/or chronic diseases including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and people with comorbidities of chronic diseases, with an estimated hospitalization rate of 3 Percent. Finally the Low risk This includes people who do not belong to the high or medium risk categories and have a low risk of hospitalization (0.5%). Most people are at low risk.
The new recommendations published by the BMJ are part of a Life guidelines, prepared by WHO with methodological support from the MAGIC Evidence Ecosystem Foundation. Integrate the instructions the latest findings from clinical studies on existing and new therapies for Covid-19and considers evidence related to safety, prognosis, resources, access and equity issues, and patient values and preferences.
Therefore, the updates include a new therapeutic benefit threshold of 1.5 percent (compared to 6 percent) reduction in the risk of hospitalization. This reflects the lower baseline risk for the majority of patients with non-severe Covid-19, as well as a greater security proof and a greater availability of therapies.
Treatments against Covid-19
As for treatment, its use is recommended now antiviral drug Nirmatrelvir-ritonavir (also known by the trade name Paxlovid) in patients with non-severe Covid-19 at high and intermediate risk of hospitalization. This is what the recommendations specify Nirmatrelvir-ritonavir Due to therapeutic benefits, ease of administration, and reduced concerns about potential harm, it is considered the best option for most eligible patients.
The OMS advises against the use of molnupiravir and remdesivir in patients at moderate risk, taking into account that the potential harms outweigh the limited benefit in patients at moderate risk of hospitalization. For people at low risk of hospitalization: does not recommend antiviral therapy. Symptoms such as fever and pain can still be controlled with painkillers such as paracetamol.
Also taken into consideration is a urgent recommendation against the use of a new antiviral agent (VV116) for patients with Covid-19 except in clinical trials, regardless of the severity of the disease. This also includes a specific recommendation against the use of ivermectin in patients with non-severe Covid-19 – the use of ivermectin in patients with severe or critical Covid-19 is also still not recommended, except in clinical trials -.
Experts say the new recommendations reflect this Changes in virulence and transmissibility circulating SARS-CoV-2 variants and subvariants, and changes in immunity associated with global vaccinations, which have resulted in a lower initial risk of severe disease and death in the majority of non-severe Covid-19 patients.
However, these experts recognize this “Uncertainties” still exist. around Covid-19 therapeutics and new evidence and state that these recommendations should be applied in light of these inaccuracies.